Journal
MEDCHEMCOMM
Volume 6, Issue 7, Pages 1381-1386Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5md00152h
Keywords
-
Funding
- AbbVie [1097737]
- Bayer
- Boehringer Ingelheim
- Canada Foundation for Innovation
- Canadian Institutes for Health Research
- Genome Canada
- GlaxoSmithKline
- Janssen
- Lilly Canada
- Merck
- Novartis Research Foundation
- Ontario Ministry of Economic Development and Innovation
- Pfizer
- Takeda
- Wellcome Trust [092809/Z/10/Z]
- European Union the Biotechnology and Biological Sciences Research Council (BBSRC)
- British Heart Foundation
Ask authors/readers for more resources
Emerging evidence suggests bromodomain-containing proteins 7 and 9 (BRD7 and BRD9) have roles in the regulation of human transcription and disease including cancer. We describe potent and selective inhibitors of the BRD7 and BRD9 bromodomains intended for use as tools to elucidate the biological roles of BRD7 and BRD9 in healthy and diseased cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available